GLYC - GlycoMimetics A Buy On Nearing Trial Enrollment Completion November, 12 2021 05:33 PM GlycoMimetics Inc. GlycoMimetics’ main AML trial is close to completion of enrollment. Uproleselan Phase 3 trial likely to build on prior positive data. Results from a National Cancer Institute trial could expand the label. For further details see: GlycoMimetics A Buy On Nearing Trial Enrollment Completion